Wright Medical Group, Inc. Announces Commercial Launch of INFINITY® Total Ankle System
Third Generation System Extends Leadership Position in Treating End-Stage Ankle Arthritis
MEMPHIS, Tenn.--(BUSINESS WIRE)--Wright Medical Group, Inc. (NASDAQ: WMGI) today announced the full U.S. commercial launch of its INFINITY® Total Ankle Replacement (TAR) System. The system is now available in the U.S. through Wright Medical’s foot and ankle sales force. The INFINITY® TAR System will also be available on a limited basis in select countries outside the U.S. through Wright’s direct sales organization.
The INFINITY® TAR System combines a low-profile implant design and seamless integration with PROPHECY® Pre-Operative Navigation Alignment Guides (presentation: http://phx.corporate-ir.net/phoenix.zhtml?c=129751&p=irol-irhome). It also features a distinctive talar resurfacing option for preservation of talar bone and a tibia design that is compatible with the Company’s existing INBONE® II System.
Dr. Robert Anderson, foot and ankle surgeon at OrthoCarolina in Charlotte, North Carolina, stated, “The INFINITY total ankle system represents a breakthrough in treating end-stage ankle arthritis patients in that I now have the option of a low profile, bone conserving total ankle system that is fully integrated with the proven accuracy and reproducibility of PROPHECY pre-operative navigation. Importantly, the talar component of the INFINITY ankle system is interchangeable with the INBONE II system, which allows me to provide a true continuum of care for my total ankle replacement patients. In addition to the many patient-centered attributes of the INFINITY total ankle, my experience has been that procedure times with the INFINITY ankle with PROPHECY can be on par with fusion procedure times. I believe the result of these significant improvements in total ankle design and technique can be a win-win for end-stage ankle arthritis patients and physicians.”
Key features of the new INFINITY® Total Ankle System include:
- Low-profile implant design – anterior cortex sparing tibial component design
- Compatibility with INBONE® II talar components – provides flexibility and opportunity to address continuum of care
- Seamless integration with PROPHECY® Pre-Operative Navigation Guides – offers fewer surgical steps, less fluoroscopic exposure and reduced surgical time
Robert Palmisano, president and chief executive officer, commented, “The launch of our INFINITY ankle extends our leadership position and multi-year competitive lead in total ankle technology and represents a significant near-term opportunity for Wright. This technology, combined with our new, streamlined go-to-market program should enhance our ability to lead in this underpenetrated market. With the addition of INFINITY to our existing ankle portfolio, which includes the widely acclaimed INBONE total ankle system, Wright is first to offer best-in-class total ankle replacement systems that address the continuum of care for end-stage ankle arthritis patients. We believe INFINITY’s lower profile design and straightforward surgical approach expands our access to less complicated primary cases and will be an important catalyst in the ongoing market conversion from fusion procedures to total ankle replacement.”
More information on Wright Medical’s foot and ankle products can be found at www.wmt.com/footandankle/.
About Wright Medical
Wright Medical Group, Inc. is a specialty orthopaedic company that provides extremity and biologic solutions that enable clinicians to alleviate pain and restore their patients’ lifestyles. The company is the recognized leader of surgical solutions for the foot and ankle market, one of the fastest growing segments in medical technology, and markets its products in over 60 countries worldwide. For more information about Wright Medical, visit www.wmt.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements,” as defined under U.S. federal securities laws, concerning, among other things, the clinical performance and anticipated market acceptance of the INFINITY® total ankle replacement system. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current view of future performance, results, and trends. Forward-looking statements may be identified by their use of terms such as anticipate, believe, could, estimate, expect, intend, may, plan, predict, project, will, and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The reader should not place undue reliance on forward-looking statements. Such statements are made as of the date of this press release, and we undertake no obligation to update such statements after this date. Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements in this press release include the risk that for any reason the INFINITY® total ankle replacement system is not well accepted by surgeons, the risk that competitive products are considered clinically or economically superior due to performance, pricing, product bundling or other factors, and the risk that for any reason ankle fusion procedures continue to dominate the end stage ankle arthritis market. Additional risks and uncertainties are discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2013, and as may be supplemented in our Quarterly Reports on Form 10-Q).